Sartorius Stedim Biotech and Refine Technology Announce Cooperation
Sartorius Stedim Biotech (SSB) and Refine Technology (Refine) will be collaborating on the development of a robust platform for high-density cell cultivation. This platform will enable fast, easy connection of the ATF System to SSB’s single-use BIOSTAT® bioreactors.
This joint development project proactively responds to the current market demand for more effective connectivity between equipment from different suppliers to enable development of efficient, streamlined systems. “We decided to work together, based on market feedback, to create a better platform for late-stage clinical and commercial-scale biopharmaceutical manufacturing processes. Our objective is to give our customers the confidence of a well-thought-out system featuring optimal and robust high-density cell cultivation via perfusion and concentrated fed-batch processes,” stated Christel Fenge, Vice President of Fermentation Technologies at SSB.
“The market demand for cell retention systems is expanding rapidly and we are pleased to be working with Sartorius Stedim Biotech to ensure that the ATF System integrates effortlessly with the BIOSTAT bioreactors. Our objective is to dramatically reduce the risk and cost of upstream processing through continuous culture and process intensification,” explained John Bonham-Carter, Vice President of Sales and Business Development at Refine.
Other news from the department business & finance
